These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2956231)

  • 61. [Effects of 14-member cyclic macrolide compounds on rat leukocyte chemotaxis].
    Obori M; Otoguro K; Suzuki K; Sunazuka K; Kobata R; Iwai J; Omura S
    Jpn J Antibiot; 2000 Jan; 53 Suppl A():85-8. PubMed ID: 10756460
    [No Abstract]   [Full Text] [Related]  

  • 62. Influence of amoxycillin, erythromycin and roxithromycin on colonization resistance and on appearance of secondary colonization in healthy volunteers.
    Vollaard EJ; Clasener HA; van Griethuysen AJ; Janssen AJ; Sanders-Reijmers AJ
    J Antimicrob Chemother; 1987 Nov; 20 Suppl B():131-8. PubMed ID: 3429382
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antimycoplasma activities of macrolide antibiotics.
    Omura S; Hironaka Y; Nakagawa A; Umezawa I; Hata T
    J Antibiot (Tokyo); 1972 Feb; 25(2):105-8. PubMed ID: 5034806
    [No Abstract]   [Full Text] [Related]  

  • 64. Hydroxylation and N-demethylation of clarithromycin (6-O-methylerythromycin A) by Mucor circinelloides.
    Adachi T; Sasaki J; Omura S
    J Antibiot (Tokyo); 1989 Sep; 42(9):1433-7. PubMed ID: 2529234
    [No Abstract]   [Full Text] [Related]  

  • 65. Factors affecting the in-vitro activity of roxithromycin.
    Andrews JM; Ashby JP; Wise R
    J Antimicrob Chemother; 1987 Nov; 20 Suppl B():31-7. PubMed ID: 3123452
    [TBL] [Abstract][Full Text] [Related]  

  • 66. In-vitro activity of clarithromycin (A-56268; TE-031) against gram-positive bacteria.
    Rolston K; Gooch G; Ho D
    J Antimicrob Chemother; 1989 Mar; 23(3):455-7. PubMed ID: 2525120
    [No Abstract]   [Full Text] [Related]  

  • 67. Macrolide progress.
    Wise R
    J Antimicrob Chemother; 1990 Jul; 26(1):5-6. PubMed ID: 2145255
    [No Abstract]   [Full Text] [Related]  

  • 68. Unpredictable influence of human serum on antimicrobial activity of erythromycin and three oxime ether macrolides.
    Jones RN; Barry AL
    Eur J Clin Microbiol; 1987 Feb; 6(1):81-2. PubMed ID: 3569260
    [No Abstract]   [Full Text] [Related]  

  • 69. Effects of roxithromycin, a new semisynthetic macrolide, and two erythromycins on drug metabolizing enzymes in rat liver.
    Villa P; Sassella D; Corada M; Bartosek I
    J Antibiot (Tokyo); 1988 Apr; 41(4):563-9. PubMed ID: 3372362
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Further studies on the effect of agents on regeneration of corneal epithelium.
    MARR WG; WOOD R; GRIEVES M
    Am J Ophthalmol; 1954 Apr; 37(4):544-8. PubMed ID: 13148284
    [No Abstract]   [Full Text] [Related]  

  • 71. [New aspects of macrolides: contribution of roxithromycin].
    Bertrand A; Jonquet O
    Rev Med Interne; 1987; 8(5):527-32. PubMed ID: 3328252
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Macrolides: problems and promises.
    Neu HC
    J Clin Pharmacol; 1988 Feb; 28(2):153-5. PubMed ID: 3360967
    [No Abstract]   [Full Text] [Related]  

  • 73. Synthetic studies of erythromycin derivatives. Synthesis and antimicrobial activities of 3''-EPI-erythromycin A and (9S)-11-dehydroxy-9-deoxo-9-hydroxy-11- oxoerythromycin A.
    Nakata M; Tamai T; Miura Y; Kinoshita M; Tatsuta K
    J Antibiot (Tokyo); 1993 May; 46(5):813-26. PubMed ID: 8514636
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Activity of quinolones against Legionellaceae.
    Pohlod DJ; Saravolatz LD
    J Antimicrob Chemother; 1986 Apr; 17(4):540-1. PubMed ID: 3710961
    [No Abstract]   [Full Text] [Related]  

  • 75. Susceptibility of Legionella spp. to quinolone derivatives and related organic acids.
    Ruckdeschel G; Ehret W; Ahl A
    Eur J Clin Microbiol; 1984 Aug; 3(4):373. PubMed ID: 6489330
    [No Abstract]   [Full Text] [Related]  

  • 76. Preparation and in vitro antibacterial activity of 6-O-methylerythromycin D.
    Gracey HE; Montgomery SH; Liu JH; Nilius A; Celebuski JE
    J Antibiot (Tokyo); 1999 Sep; 52(9):831-4. PubMed ID: 10726932
    [No Abstract]   [Full Text] [Related]  

  • 77. Isolation and characterization of sporeamicin B.
    Morishita A; Murofushi S; Ishizawa K; Mutoh N; Yaginuma S
    J Antibiot (Tokyo); 1992 May; 45(5):809-12. PubMed ID: 1624386
    [No Abstract]   [Full Text] [Related]  

  • 78. Acid degradation studies of 6-deoxyerythromycin A.
    Faghin R; Pagano T; McAlpine J; Tanaka K; Plattner J; Lartey P
    J Antibiot (Tokyo); 1993 Apr; 46(4):698-700. PubMed ID: 8501017
    [No Abstract]   [Full Text] [Related]  

  • 79. Synthesis and antibacterial activity of 6-deoxysporeamicin A.
    Faghih R; Freiberg L; Leonard J; Plattner JJ; Lartey PA
    J Antibiot (Tokyo); 1996 May; 49(5):493-5. PubMed ID: 8682729
    [No Abstract]   [Full Text] [Related]  

  • 80. Intracellular killing of Legionella by erythromycin.
    Miller MF; Martin JR; Levy NL
    Lancet; 1984 Feb; 1(8372):348-9. PubMed ID: 6141419
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.